ICU Medical has delivered a perfect four-quarter earnings beat streak with outstanding cash conversion, but the shares already trade above the analyst target and growth is weak, leaving no upside cushion.
Thesis pillars
- Perfect Earnings Beat Streak→Stable
- Price Above Analyst Target↓Deteriorating
- Single Supplier Concentration→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 14, 2026, based on the 10-K filed Feb 19, 2026
ICU Medical, Inc. (ICUI) Stock Analysis
Breakout setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $181.87 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single supplier.
ICU Medical develops, manufactures, and sells medical devices for infusion therapy, vascular access, and vital care, serving acute care hospitals, ambulatory clinics, and long-term care facilities in over 100 countries. Revenue flows through direct sales and distributors... Read more
Sell if holding. Analyst target reached at $181.87 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single supplier. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Score 5.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 93d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
No fresh coverage since Oct 31, 2026
Recent Developments — ICU Medical, Inc.
Latest news
- NEWS Earnings Preview: ICU Medical to Report Financial Results Post-market on November 05 - Moomoo — Moomoo Oct 31, 2026 neutral
- NEWS ICUI Q3'26 Earnings: revenue estimate is 552.07M USD - TradingView — TradingView Oct 29, 2026 neutral
- NEWS ICU Medical (ICUI) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance — Yahoo Finance Aug 6, 2026 positive
- NEWS ICU Medical (ICUI) Reports Q2 Earnings: What Key Metrics Have to Say - finance.yahoo.com — finance.yahoo.com Aug 6, 2026 positive
- NEWS ICU Medical (ICUI) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance Aug 6, 2026 positive
Latest item Oct 31, 2026 · Generated 2026-11-17T11:57:21Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomersingle distributor18%10-K Item 1: 'we had worldwide net sales to a single distributor of 18%, 18%, and 16% of consolidated net sales, respectively'
- HIGHSuppliersingle supplier10-K Item 1: 'Certain components and raw materials are available only from a single supplier'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $181.87 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single supplier. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Prior stop was $169.14. Score 5.2/10, moderate confidence.
Analyst target $169.00 reached (−7.1% from $181.87); no take-profit level is published. Prior stop was $169.14. Stop-loss: $169.14.
Concentration risk — Supplier: single supplier; Analyst target reached - limited upside remaining; Weak growth.
ICU Medical, Inc. trades at a P/E of 76.1 (forward 18.8). TrendMatrix value score: 5.8/10. Verdict: Sell.
13 analysts rate ICUI, with a consensus score of 4.3/5. 8 analysts publish price targets averaging $194.
What does ICU Medical, Inc. do?ICU Medical develops, manufactures, and sells medical devices for infusion therapy, vascular access, and vital care,...
ICU Medical develops, manufactures, and sells medical devices for infusion therapy, vascular access, and vital care, serving acute care hospitals, ambulatory clinics, and long-term care facilities in over 100 countries. Revenue flows through direct sales and distributors globally, with a single distributor accounting for 18% of consolidated net sales in 2025. In May 2025, ICU closed a transaction transferring its IV Solutions business to a joint venture with Otsuka Pharmaceutical Factory America, retaining a 40% stake.